Datar Cancer Genetics

Offers liquid biopsy biomarker testing plus ex vivo drug response testing on tumor tissue.

Vetted listing

Testing2 offerings

Consented intake · your records travel with you · nothing moves without your sign-off

Why Datar exists

Datar Cancer Genetics combines liquid biopsy with functional testing. It analyzes blood and other fluids for biomarkers that can guide treatment and monitor disease, and applies drugs to fresh tumor tissue ex vivo to observe response. For patients weighing drug options, this adds direct evidence of how their own cancer cells respond before committing.

CLIA certified and CAP accredited laboratoriesUKAS accredited · Medical Laboratory No. 22238, UKUS FDA cleared · Comprehensive genomic profilingLaboratories · Nashik, India and Guildford, UK

Prefer the source? Datar Cancer Genetics's own site has more.

Share your records

We'll pre-fill the intake from your records — no retyping.

Start sharing →

Check your coverage

See if your insurance covers this and estimate out-of-pocket cost.

Check coverage →

What they offer

Testing· 2

Provide greater confidence that the patient will respond to a drug or combination from “ex vivo” test results
Gather distinctive biomarkers that can guide treatment and monitor disease progression

Coverage, insurance & cost

The fastest way to know what you'll pay: check your coverage with your plan. Below is what we know about how Datar Cancer Genetics handles billing.

We don't have confirmed insurance details for Datar Cancer Genetics yet. Start a coverage check with your plan, or contact the provider directly.

Ask about this service

Answers grounded in Datar's details here. Educational only; your oncologist directs treatment.

Ask OpenCancer · answers grounded in this storefront

Who this is for

Cancer types served

all cancer types

Also consider

Other providers in similar categories.

BostonGene

6 offerings

Gather distinctive biomarkers that can guide treatment and monitor disease progression

Foundation Medicine

6 offerings

FoundationOne CDx is an FDA-approved comprehensive genomic profiling test that analyzes 324 genes to identify clinically relevant genomic alterations.